Target intelligence / Profile preview

Vaccinia virus D10 decapping enzyme (D10)

Target
D10
Molecular classification
Enzyme, Nudix hydrolase family, Viral protein
01

Overview

The D10 decapping enzyme of vaccinia virus is a member of the Nudix hydrolase family, characterized by its conserved Nudix/MutT motif, which is required for its pyrophosphatase activity and substrate recognition. D10 is responsible for removing the 5’ methyl-G cap from both host and viral mRNAs, leading to rapid mRNA degradation during infection. This activity helps the virus suppress host gene expression and preferentially promote viral mRNA translation, particularly for viral transcripts containing a long poly(A) leader at the 5’ end. D10 is a promiscuous enzyme, targeting most cellular mRNAs (especially those from intron-containing genes) for degradation, while sparing intronless viral transcripts. This selectivity is believed to facilitate viral protein synthesis and modulate apoptosis, thereby optimizing viral replication. D10 has constitutive decapping activity, in contrast to tightly regulated cellular decapping enzymes, and its activity is essential for the vaccinia virus’ manipulation of host gene expression and translation.

Other names
D10 proteinVACV D10vaccinia decapping enzymeNudix hydrolase D10
02

Mechanism of action

inhibiting enzymatic decapping activity—preventing removal of the 5’ cap from mRNA, thus blocking mRNA degradation.

03

Biological functions

mRNA decappingmRNA turnover/degradationNegative regulation of host and viral gene expressionSelective translation activation of viral mRNAs with poly(A) leaders
04

Disease associations

Infection (poxvirus, specifically vaccinia virus)Modulation of host cellular response and apoptosis
05

Safety considerations

Therapeutic inhibition of D10 could alter viral replication dynamics and host cell death during infectionBroad inhibition could affect overall viral-host interactions and immune modulationNo direct safety studies are reported
06

Interacting drugs

nucleoside analogs (in vitro inhibitors)

1 more in the full profile.

07

Biomarkers

No validated clinical biomarkers for D10 activity or patient selectionLevels of capped mRNA (research biomarker)Host apoptosis-related transcript abundance (research biomarker)

Beyond the preview

Go deeper on Vaccinia virus D10 decapping enzyme (D10).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaccinia virus D10 decapping enzyme (D10).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call